Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use.
Vaccine
; 15(14): 1562-7, 1997 Oct.
Article
en En
| MEDLINE
| ID: mdl-9330469
ABSTRACT
Mice vaccinated with a recombinant protein containing the two EGF-like modules of Plasmodium yoelii merozoite surface protein-1 in liposomes or combined with the formulations SBAS2.1 and SBAS2, were protected against a lethal malaria infection. The protection achieved with these adjuvants developed for clinical use was as good as or better than that achieved with Freund's adjuvant. A parasite-specific response was needed for protection. Analysis of the immunoglobulin sub-class response showed that MSP-1-specific IgG1, and to a lesser extent IgG2a and IgG2b, were induced, suggesting that these antibodies were important for protection. Mice passively immunized with serum or purified IgG from vaccinated mice had delayed onset of parasitemia and were able to control the infection.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Fragmentos de Péptidos
/
Precursores de Proteínas
/
Plasmodium yoelii
/
Vacunas Sintéticas
/
Proteínas Protozoarias
/
Vacunas contra la Malaria
Límite:
Animals
Idioma:
En
Revista:
Vaccine
Año:
1997
Tipo del documento:
Article
País de afiliación:
Reino Unido